News Vertex's Orkambi CF drug okayed for funding in Australia Committee recommends outcomes-based deal
News Spark shares tank after haemophilia gene therapy safety sign... Biotech still pressing on with late stage trials
Partner Content Partner Content How challenges like Brexit & insufficient patients hinde... Challenges facing Orphan Drugs & Rare Diseases Research
Events Partner Content Orphan Drugs & Rare Diseases 2018 Orphan Drugs & Rare Diseases 2018 Conference
News NHS does not value CF patients, says Vertex CEO in letter to... But Vertex dismisses rumours it will quit the UK
News Ultragenyx to slash costs after Angelman trial failure Ultragenyx's therapy for the rare genetic disorder Angelman syndrome, apazunersen, has flunked a late-stage trial, crashing its share price.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
